Tuesday, August 21, 2018
 
 
Company News: Page (1) of 1 - 02/08/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
RESULTS OF ELECTION OF DIRECTORS AT 2017 MEETING OF SHAREHOLDERS OF SINOVAC BIOTECH ARE OUT

(February 08, 2018)

BEIJING, CHINA - February 8, 2018 - Shandong Sinobioway Biomedicine Co., Ltd. (SZSE: 002581) (“Shandong Sinobioway”) announced today that it has learned that at the close of the 2017 Annual Meeting of Shareholders of Sinovac Biotech Ltd. (NasdaqGS: SVA) (“Sinovac Biotech” or the “Company”) held yesterday morning, the Company’s inspector of elections, Helen Yang, announced the results of the matters voted at the meeting.  Four nominees, Guowei Wang, Hoi Fung Qiu, Jianzeng Cao, and Pengfei Li, and one of the incumbent directors, Yuk Lam Lo, received 55.19 percent of all votes present and voting at the meeting.  Four members of the incumbent board, Weidong Yin, Kenneth Lee, Meng Mei and Simon Anderson, were defeated by the same margin.  

Shandong Sinobioway,on behalf of Sinobioway Consortium, issued the following statement:

“Sinobioway Consortium applauds the Company’s shareholders for electing Guowei Wang, Hoi Fung Qiu, Jianzeng Cao, Pengfei Li, and Yuk Lam Lo.  This is a milestone event in the history of shareholder democracy and corporate governance.  We look forward to their prompt installation and wish both them and the Company great success under their stewardship.”



About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), and mumps. The EV71 vaccine, an innovative vaccine developed by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. The Company is developing a number of new products including a Sabin-strain inactivated polio vaccine, pneumococcal polysaccharides vaccine, pneumococcal conjugate vaccine and varicella vaccine. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company has exported select vaccines to over 10 countries in Asia and South America.  

Media Contact
Company Name: Shandong Sinobioway Biomedicine Co., Ltd.
Contact Person: Yizhe Wang
Email: [email protected]
Country: China
Website: http://www.sdsinobioway.com/




Page: 1


Related Keywords:Technology,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Neurovascular Devices Market High Revenue at USD 24,650 mn by 2023 | Therapeutic Application Hemorrhagic & Ischemic Strokes | Worldwide Segmentation by MRFR
  • The global connected health device market is expected to reach an estimated $36.1 billion by 2023 and is forecast to grow at a CAGR of 21.1% from 2018 to 2023
  • Global Hemodialysis and Peritoneal Dialysis Market to Witness a CAGR of 5.9% during 2018-2024
  • The Alzheimer's Research and Prevention Foundation (ARPF) Announces Second Brain Longevity® Therapy Training Program in Washington D.C.
  • Image Guided Radiotherapy Market to Experience Unfaltering Growth at 15.8% CAGR to Revolutionize the Healthcare Sector by 2023

    Cancer
  • New ESMO Tumour DNA Scale Helps Match Patients with Cancer to Optimal Targeted Medicines
  • /R E P E A T -- Information Update - Teva Canada expands recall of valsartan drugs to include additional lots, as a precaution/
  • Singapore's first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer
  • Information Update - Teva Canada expands recall of valsartan drugs to include additional lots, as a precaution
  • ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines